NEW YORK, July 12, 2025 — Pomerantz LLP announced that a class action lawsuit has been initiated against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Investors impacted are advised to reach out to Danielle Peyton at or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those inquiring via e-mail should include their mailing address, telephone number, and the number of shares acquired.

The class action aims to determine whether Rocket and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.

If you acquired Rocket securities during the Class Period, you have until August 11, 2025 to petition the Court for appointment as Lead Plaintiff for the class. A copy of the Complaint can be obtained at .

On May 27, 2025, Rocket released a statement providing an “update regarding RP-A501, its experimental gene therapy for Danon disease.” The release revealed that a patient in the Phase 2 pivotal trial for RP-A501 suffered an “unexpected Serious Adverse Event (SAE)” characterized by “clinical complications associated with a capillary leak syndrome.” The press release stated that “Rocket voluntarily halted further dosing in the study immediately upon becoming aware of the event,” and that “on May 23, 2025, the FDA imposed a clinical hold on the trial to facilitate additional assessment.” The press release concluded by mentioning that the patient subsequently “died following an acute systemic infection.”

Following this announcement, Rocket’s stock price dropped by $3.94 per share, representing a 62.84% decline, closing at $2.33 per share on May 27, 2025.

Pomerantz LLP, with branches in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, holds a reputation as a leading firm in corporate, securities, and antitrust class action litigation. Established by the late Abraham L. Pomerantz, who was recognized as the dean of the class action bar, Pomerantz was a pioneer in securities class actions. Over 85 years later, the firm upholds his legacy, advocating for the rights of those affected by securities fraud, breaches of fiduciary duty, and corporate misbehavior. The Firm has secured many multi-million dollar damage awards for class participants. More information is available at .

This is attorney advertising. Past results do not assure comparable future outcomes.

FOR CONTACT:
Danielle Peyton
Pomerantz LLP

646-581-9980 ext. 7980

SOURCE: Pomerantz LLP